Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial

Epilepsia

Volumn 55, Issue 1, 2014, Pages 38-46

  Kwan, Patrick ^a,b   Trinka, Eugen ^c   Van Paesschen, Wim ^d   Rektor, Ivan ^e   Johnson, Martin E ^f   Lu, Sarah ^f  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Christian Doppler Klinik   (Austria)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e MASARYK UNIVERSITY   (Czech Republic)

^f UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drug; Brivaracetam; Epilepsy; Seizures; Synaptic vesicle protein 2A

Indexed keywords

BRIVARACETAM; ETIRACETAM; PLACEBO;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; AGGRESSION; ARTICLE; BACKACHE; BEHAVIOR DISORDER; CHRONIC PANCREATITIS; CONTROLLED STUDY; CONVULSION; DIZZINESS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HUMAN; IRRITABILITY; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUS BRADYCARDIA; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT;

ANTIEPILEPTIC DRUG; BRIVARACETAM; EPILEPSY; SEIZURES; SYNAPTIC VESICLE PROTEIN 2A;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; HUMANS; MIDDLE AGED; PYRROLIDINONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892932590     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12391     Document Type: Article

References (18)

1. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U,. (2007) Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy; Levetiracetam N01057 Study Group. Neurology 69: 1751-1760.
2. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ,. (2007) Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68: 402-408.
3. Brodsky A, Costantini C, von Rosenstiel P,. (2007) Safety and tolerability of brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 48 (Suppl. 6): 3.256. Abstract.
4. Delanty N, Jones J, Tonner F,. (2012) Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia 53: 111-119.
5. French JA, Costantini C, Brodsky A, von Rosenstiel P,. (2010) Adjunctive brivaracetam for refractory partial-onset seizures. A randomized, controlled trial. Neurology 75: 519-525.
6. Hernandez-Diaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB,. (2012) Comparative safety of antiepileptic drugs during pregnancy. Neurology 78: 1692-1699.
7. International League Against Epilepsy. (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30: 389-399.
8. Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR, Fuks B, Michel P,. (2004) Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 47: 530-549.
9. Matagne A, Margineanu D-G, Kenda B, Michel P, Klitgaard H,. (2008) Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 154: 1662-1671.
10. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J,. (2006) Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77: 193-198.
11. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann Delgado J, N166 Levetiracetam Study Group. (2008) Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70: 607-616.
12. Rheims S, Perucca E, Cucherat M, Ryvlin P,. (2011) Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 52: 219-233.
13. Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA,. (2011) Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 76: 383-389.
14. Somerville ER,. (2009) Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy). Epilepsia 50 (Suppl. 8): 31-36.
15. St Louis EK,. (2009) Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care. Curr Neuropharmacol 7: 106-114.
16. Vajda FJ, Graham J, Roten A, Lander CM, O'Brien TJ, Eadie M,. (2012) Teratogenicity of the newer antiepileptic drugs-the Australian experience. J Clin Neurosci 19: 57-59.
17. van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P,. (2013) Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 54: 89-97.
18. Werhahn KJ, Biton V, Johnson ME, Merschhemke M, Lu S, N01252 and N01253 Brivaracetam Study Group. (2010) Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from two randomized, double-blind, placebo-controlled trials. Epilepsia 51 (Suppl. 4):Abstract p507.